Advertisement

Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 268–271 | Cite as

Liver Transplantation for Hepatocellular Carcinoma at Inonu University

  • Cuneyt KayaalpEmail author
  • Volkan Ince
  • Veysel Ersan
  • Serdar Karakas
  • Aysegul Sagir Kahraman
  • Sezai Yilmaz
Review Article
  • 87 Downloads

Abstract

There is a great effort in the world to find a new drug in hepatocellular carcinoma (HCC) treatment. Turkey has a limited number of basic science studies to discover a new therapeutic drug for HCC. It seems that Turkey is distanced from the global drug discovery race and competition, however, Turkey has the advantage of a wide experience in living donor liver transplantation, like South Korea and Japan. Turkey can plan new studies on HCC, particularly with living donor liver transplantation. Neoadjuvant treatment methods before living donor liver transplantation for advanced tumors would be a good idea for study in Turkey. Because Inonu University has the busiest liver transplantation program in Turkey, the contribution of Inonu University to trials like this can improve the depth of the studies. To conclude, the Inonu University Liver Transplantation Institute has the busiest program in Turkey with 1,600 transplantations in eight years. The program is based on living donor liver transplantations (80%). Living donor liver transplantation for advanced HCC patients is our favorite topic to study.

Keywords

Liver transplantation Hepatocellular carcinoma Living donation Tumor staging Survival 

Notes

Compliance with Ethical Standards

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Isik B, Ince V, Karabulut K, Kayaalp C, Yilmaz S. Living donor liver transplantation for hepatocellular carcinoma. Transplant Proc. 2012;44:1713–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Akbulut S, Kayaalp C, Yilmaz M, Ince V, Ozgor D, Karabulut K, et al. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients. World J Gastroenterol. 2013;19:1625–31.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Cuneyt Kayaalp
    • 1
    Email author
  • Volkan Ince
    • 1
  • Veysel Ersan
    • 1
  • Serdar Karakas
    • 1
  • Aysegul Sagir Kahraman
    • 1
  • Sezai Yilmaz
    • 1
  1. 1.Inonu University Liver Transplantation InstituteMalatyaTurkey

Personalised recommendations